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The advancement of molecular mediators or biologic agents has increased tremendously during the last decade in periodontology
and dental implantology. Implant site development and reconstruction of the lost periodontium represent main fields in which
these molecular mediators have been employed and investigated. Different growth factors trigger different reactions in the tissues
of the periodontium at various cellular levels. Proliferation, migration, and differentiation constitute the main target areas of these
molecular mediators. It was the purpose of this comprehensive review to describe the origin and rationale, evidence, and the
most current understanding of the following biologic agents: Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-
BB), Enamel Matrix Derivate (EMD), Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF), Recombinant Human Fibroblast
Growth Factor-2 (rhFGF-2), Bone Morphogenic Proteins (BMPs, BMP-2 and BMP-7), Teriparatide PTH, and Growth Differential
Factor-5 (GDF-5).
1. Introduction
Multiple factors and/or conditions such as periodontal dis-
eases, traumatisms, congenital abnormalities, and tumors
may result in significant loss of the periodontium and
surrounding structures. If no treatment is provided then
the risk for extensive bone defects increases and this may
eventually compromise the ability of maintaining the denti-
tion or even the overall bony structure for future prosthetic
rehabilitation.Hence, in these scenarios, not only periodontal
treatment is required but also regain of the lost structures is
recommended. Regeneration of the lost periodontium with
exact same structure has been the ideal goal in periodontal
therapy for long time [1]. However, the reestablishment of the
periodontium’s original form, shape, properties, and function
remains a clinical challenge [2]. By definition, periodontal
regeneration must achieve the regeneration of the alveolar
bone, cementum, and periodontal ligament and also promote
an adequate sealing by the gingival tissue. To do so, a
temporal sequence and specific spatial distribution of the cells
and signaling molecules involved in this particular healing
process have to be followed [3].
The specific mechanisms and events necessary for peri-
odontal regeneration to occur are not yet fully understood. It
is known however that specific cells must first attach to the
substrate before migrating and proliferating to the healing
area supported by the fibrin coagulum and attracted by
soluble factors. Once in the area, those cells will provide the
cellular and molecular machinery needed to clean the area
and initiate the growth of the new tissue. As it progresses,
extracellular matrix (ECM) and matrix-cellular proteins will
secure the area so that differentiated populations can act to,
ultimately, establish a functional tissue with the appropriate
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Since its development in 1980s [5–7], guided tissue
regeneration (GTR) has been extensively studied. With the
vast amount of clinical and preclinical studies, it has been
demonstrated that contained defects, such as 3-walled intra-
bony and class two furcations, can predictably be regenerated
with the employment of multiple grafting materials and/or
barrier membranes [8]. However, when significant tissue
regeneration is needed or in the presence of locally and/or
systemically compromised scenarios (i.e., restricted blood
supply due to systemic disorder or uncontained defect),
the application of grafting materials, barrier membranes,
and/or biologic agents has to be carefully selected to promote
predictable and sufficient quantity and quality of regenerated
tissue [8]. Therefore, not only scaffolds but also ability to
inhibit invasion of certain undesired cells to the area is
needed. Nonetheless, scaffolds by themselves usually fail to
promote the adequate healing induction and conduction
needed for the repair process to occur. When it does, this
healing cannot be considered a true regeneration because it
usually promotes bone regeneration failing at reconstructing
other components of the periodontium. The application of
biologic agents emerges to compensate for such drawbacks by
mimicking, inducing, and regulating the activity of the nat-
ural events that happen in the healing area with the purpose
of promoting the regeneration of the tissue. Biologic agents
are substances made from a living organism or its products
used in the prevention, diagnosis, or treatment of a disease. In
this sense, the utilization of such biomaterials should ideally
result in faster healing and improved regenerative outcomes.
A wide variety of biomolecules, compounds, and purified
recombinant agents have been proposed (Table 1). Therefore,
the purpose of this review was to comprehensively review
each particular biologic agent and provide the rationale,
evidence, and current understanding of the effect of these
materials upon periodontal regeneration.
2. Recombinant Human Platelet-Derived
Growth Factor-BB (rhPDGF-BB)
2.1. Rationale. rhPDGF-BB represents one of themost widely
studied growth factors in the field of periodontology. Its
efficacy has been demonstrated in both hard and soft tissue
regeneration during the last decades. Specifically, PDGF-BB
is involved in wound healing stimulating the potential for
regeneration of the periodontal tissues [9]. Since it was firstly
investigated in periodontology [10], multiple studies have
then focused on a better understanding of the mechanism
of action as well as its therapeutic potential. Today, three
different forms of PDGF are known: PDGF-AA, PDGF-AB,
and PDGF-BB. After hard or soft tissue injury, PDGF is
released by blood platelets binding to specific cell surface
receptors. As a consequence, enhancement of wound healing
process by means of chemotaxis and mitogenesis occurs [11,
12]. Of particular importance for the field of periodontology
is GEM 21S, (Osteohealth, Boston, MA). Its use has been
extensively investigated in preclinical and clinical studies
including both animal and human subjects. This product
uses 𝛽-tricalcium phosphate (𝛽-TCP) as a carrier of a highly
purified rhPDGF-BB, providing physical structural support
and space maintenance.
2.2. Evidence/Indications. Numerous animal and human
studies have demonstrated its potential for periodontal
and peri-implant regeneration [10, 13–16]. Briefly, animal
studies have demonstrated that PDGF is able to promote
bone, cementum, and periodontal ligament regeneration
in periodontal defects in dogs [10]. Additionally, further
studies have investigated the potential of PDGF around
dental implants concluding that the application of PDGF/IGF
resulted in a significant increase in percentage of bone fill
and bone-to-implant contact [14]. Similarly, animal studies
conducted by Simion and coworkers [17] and Schwarz and
colleagues [18] investigated the potential of PDGF for both
vertical bone regeneration and horizontal bone regenera-
tion, respectively. Both studies have shown greater bone
regeneration when PDGF was used in combination with the
grafting material compared to using the grafting material
alone. Interestingly, in the above-mentioned studies, Simion
et al. tested the effectiveness of three different treatment
groups for vertical bone augmentation: (1) deproteinized
bovine blocks and collagen barrier, (2) deproteinized bovine
blocks with rhPDGF-BB, and (3) deproteinized bovine blocks
with rhPDGF-BB and collagen membrane. Histological and
radiographical analysis demonstrated greater bone formation
when rhPDGF-BB was utilized without collagen membrane,
suggesting that membranes block the migration of bone
forming cells from periosteum into the area of interest.
On the other hand, human studies have corroborated
the promising potential shown in both in vitro and animal
studies [16, 19, 20]. Although FDA only approved PDGF
for treatment of periodontal related defects (e.g., intrabony
defects, furcations, and gingival recessions defect), the effec-
tiveness of this biologic agent for implant related approaches
such as vertical and horizontal bone augmentation [17],
sinus augmentation procedures [21], and ridge preservation
procedures [22] has also been widely studied. Overall, results
show greater bone formation, reduced healing times, and
enhancement in the regeneration process when compared to
control groups.
2.3. Current Understanding. PDFG has been shown to pro-
mote fibroblast, cementoblast, and osteoblast migration and
proliferation into the surgical area. Currently, this agent
is being tested in multiple fields of periodontology from
recession coverage to vertical bone augmentation and the
reconstruction of peri-implant defects. Research and clinical
experience have shown its potential in improving periodontal
regeneration in a variety of clinical scenarios. Nonetheless,
longer and larger studies are still needed to further verify the
long-term effect of PDGF.
3. Enamel Matrix Derivate (EMD)
3.1. Rationale. Enamel Matrix Derivate (EMD) is composed
of different enamel related proteins, beingmainly amelogenin
(90%). It also contains proteins such as enamelin, tufflin, and
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Table 1: Summary of growth factors.
(a)
Agent rhPDGF-BB EMD PRP/PRF FGF-2





Composition Protein 90% Amelogenin PDGF, I-LGF, VEGF,TGF-𝛽 Protein
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ameloblastin, among others [23]. Embryologically, during
root development, enamel matrix proteins are secreted by
Hertwig’s epithelial root sheath, with cementogenesis being
its main function [24]. Although these proteins have shown
favorable outcomes in periodontal regeneration, resulting in
new bone formation, PDL, and cement [25], the exact mech-
anism of action remains unclear. Of particular importance
in periodontology is the commercially available product
(Emdogain, Institut Straumann AG, Basel, Switzerland).This
product is extracted from developing porcine tooth buds.
Recently, it has been demonstrated to induce the prolif-
eration of gingival mesenchymal stem cells and enhance
their osteogenic differentiation in vitro [26]. In an effort to
elucidate its mechanism of action, Schwartz and colleagues
demonstrated that EMD stimulates proliferation of pre-
osteoblasts and differentiation of osteoblast-like cells as well
as proliferation and differentiation of normal osteoblast [27].
In addition, researchers trying to elucidate its mechanism of
action have recently investigated the possible effect of this
product upon gene expression [28].
3.2. Evidence/Indications. The utilization of Emdogain has
been studied in different fields of periodontology, being
mainly intrabony and furcation defects as well as gingival
recession coverage. When examining the efficacy of EMD
for the treatment of intrabony defects, the largest study per-
formed so far concluded that EMD provides beneficial effect
in terms of CAL gain and probing depths reduction when
compared to open flap debridement alone [29]. However,
when compared with GTR, results from recent systematic
reviews found no difference between the two [30]. On the
other hand, for noncontained intrabony defects, it seems
to be a benefit of GTR over EMD alone [31]. Similarly, for
the treatment of class II furcation defects, EMD has been
employed either alone or in combinationwith a variety of dif-
ferent grafting materials reporting different grade of success
[32–34]. With regard to the treatment of recession defects,
EMD has been employed with a great variety of techniques.
In addition, most of the studies agree in the superiority of
CAF + CTG in combination with EMD when compared to
CAF alone [35, 36]. However, when compared with CAF
+ CTG, the results reported in the largest available study
have found no differences [37]. All in all, a systematic review
from the AAP Regeneration Workshop recently concluded
that although all procedures aiming at recession coverage can
provide significant reduction in both recession depth and
CAL gain, the utilization of CTG with different techniques
provides the best outcomes in terms of percentages of root
coverage and increase of keratinized tissue [38].
The utilization of EMD in different areas of the implant
field such as sinus augmentation and treatment of peri-
implantitis defects is currently being investigated [19, 39].
3.3. Current Understanding. At this moment, EMD has been
demonstrated to promote periodontal regeneration to a cer-
tain degree although its true effect remains to be determined.
In addition, EMD has been shown to influence different
genes expressed during bone remodeling (bone resorption
and formation) promoting an anabolic effect [28] as well
as enhancing osteoblast differentiation on titanium surfaces
[40]. Future studies testing the efficacy of this material
promoting guided bone regeneration (GBR) and treatment
of peri-implant defects are needed. Researches are being con-
ducted nowadays, trying to elucidate the exact mechanism of
action behind the effectiveness of EMD.
4. Platelet-Rich Plasma (PRP), Platelet-Rich
Fibrin (PRF), and Leukocyte- and Platelet-
Rich Fibrin (L-PRF)
4.1. Rationale. Derived from megakaryocytes, platelets are
small irregular anucleated cells with a diameter of 2 to 4
micrometers. Platelet average life span ranges from 8 to
12 days and the normal platelets count is defined between
150,000 and 400,000 platelets/microliter. Their key role in
hemostasis and being a natural source of growth factor
make platelets a component of paramount importance during
wound healing. Depending on the processing technique,
different types of platelets concentrates have been described
including but not limited to Platelet-Rich Plasma (PRP), Pure
Platelet-Rich Plasma (P-PRP), Leukocyte- and Platelet-Rich
Plasma (L-PRP), Platelet-Rich Fibrin (PRF), and Leukocyte-
and Platelet-Rich Fibrin (L-PRF). The potential of these
substances as a biologic agent in periodontology relies on
the growth factors stored within platelet alpha granules
containing platelet-derived growth factor (PDGF), vascular
endothelial growth factor (VEGF), insulin-like growth factor
(IGF), platelet-derived angiogenic factor, and transforming
growth factor-beta (TGF-𝛽) [41].
4.2. Evidence/Indications. PRP, PRFG, and L-PRF have been
tested as a substitute for connective tissue [42], as a graft-
ing material in sinus augmentations [43], and as a barrier
membrane for periodontal regeneration [44, 45], among
others. Nonetheless, the effectiveness of the different con-
centrates is difficult to elucidate due to the great variability
in study designs, different regimens of materials used (graft,
membrane, or combination), surgical techniques, and so
forth. Nonetheless, it has been shown to be effective in
different clinical scenarios [42, 43]. However, the results
may not be superior when compared to traditional CTG for
recession coverage [38] or traditional GTR for periodontal
regeneration [45]. On the other hand, the employment of
platelet concentrates in implant and extensive bone grafting
procedures remains to be determined.
4.3. CurrentUnderstanding. At thismoment, platelet-derived
concentrates have been shown to enhance soft tissue healing
which indirectly can create a better environment for bone
growth. However, several different concentrate products are
currently being promoted without total understanding of the
ideal component or concentration for thematerial to have the
best outcome. Some have discussed the mesh that is created
by fibrin as a key component of PRP, probably responsible for
a great part of its properties [46]. Studies in the field are highly
recommended.
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5. Recombinant Human Fibroblast Growth
Factor-2 (rhFGF-2)
5.1. Rationale. Discovered in 1970s as a protein inducing
proliferative activity in fibroblasts, FGF-2 belongs to an
extensive family with more than 20 members with similar
characteristics [47]. Among all the FGFs family, FGF-2 is
the most extensively studied in regenerative medicine and
periodontal tissue regeneration.This protein has been studied
in medicine for treatment of ulcers and bone fractures due to
its potential to facilitate revascularization [47]. Additionally,
in vivo studies have shown that FGF-2 promotes proliferation
of osteoblast accelerating bone formation [48, 49]. Further
animal studies have confirmed that local application of FGF-
2 significantly enhances periodontal regeneration compared
to control sites [50, 51]. Among its effects, FGF-2 has been
shown to promote endothelial cell proliferation [52]. In
addition, FGF-2 possesses a potent angiogenic andmitogenic
activity on mesenchymal cells within PDL [53].
5.2. Evidence/Indications. FGF-2 has not been extensively
studied yet in the field of periodontics. Nonetheless, sev-
eral animal studies have shown that this growth factor is
effective in enhancing the periodontal regeneration process
for class II furcation defects in animal models [50]. For
periodontal regeneration in humans, although histological
results have not been yet investigated, FGF-2 has been shown
to significantly improve the percentage of bone fill compared
to vehicle alone [54]. In the largest available study so far
comparing different concentrations of FGF-2 and a vehicle,
results showed significant superiority of percentage of bone
fill in FGF-2 treated sites at 36 weeks [55]. Consequently,
recent systematic reviews have concluded that although
scarce available evidence suggests that FGF-2 significantly
improves defect fill but it does not have an effect on clinical
attachment level gain [56].
5.3. Current Understanding. At this moment, the effect of
FGF-2 remains to be determined. Future studies should
continue focusing on exploring its efficacy, safety, and proper
dosage for FGF-2 to be effective in different clinical scenarios.
6. Bone Morphogenic Proteins
(BMPs, BMP-2 and BMP-7)
6.1. Rationale. BMPs are members of the transforming
growth factor-beta (TGF-𝛽) superfamily which have demon-
strated high osteoinductive potential [57]. In the periodontics
arena, both BMP-2 and BMP-7 stimulate PDL cell differ-
entiation into osteoblasts and increase expression of miner-
alized tissue markers [58, 59]. Moreover, BMPs have been
demonstrated to downregulate the mineralization process of
cementoblasts. Additionally, their employment in the implant
field relies on BMPs having the properties to modulate
bone formation, contour, and density through endochondral
formation [60] and bone formation by autoinduction [61].
Induction and maintenance of bone formation by the TGF-
𝛽 family of proteins occur in a synergistic and synchronous
way [61] with a wide variety of different proteins acting in the
process [62].
6.2. Evidence/Indications. Its application for periodontal
regeneration led to its use in implant site development (i.e.,
ridge preservation and sinus augmentation). It has to be noted
that, when aiming at the reconstruction of the periodon-
tium, although successful regeneration has been achieved in
intrabony and furcation defects [63], complications such as
ankylosis and root resorption were described [64].
rhBMP-2 (Infuse Bone Graft by Medtronic Inc.) has
recently been approved by the FDA as an alternative to
autologous bone grafting for sinus augmentation and ridge
preservation procedures owing to its osteoinductive potential
[65]. Clinical and histologic outcomes obtained for sinus
augmentation showed similar pattern to autogenous bone
in terms of bone quality and quantity [66]. Nonetheless, if
rhBMP-2 is grafted in combination with autologous bone
it seems to further increase cell activity, osteoid lines, and
vascular supply, which may lead to more predictable results
[66, 67]. On the other hand, Kao et al. showed that when
blending rhBMP-2 with bovine-derived xenogeneic graft
(Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland) a
detrimental effect occurs by means of cellular behavior and
vital bone formation. This fact might be explained due to the
enhancement of osteoclast differentiation by the adjustment
of RANKL [68]. Nonetheless, multiple studies have demon-
strated the safety of BMP-2 by lacking of immune response
[66–69].
Additionally, rhBMP-2 has been studied for alveolar ridge
augmentation/preservation. Although in vivo data is very
limited, it was found to be successful in preventing socket
from collapse by minimizing the horizontal bone resorption
[70–72]. In this study, it was also demonstrated that the
dose-dependent effect of the protein of 1.5mg/mL shows
better results than 0.75mg/mL. It has also been shown to
improve the results of sinus bone augmentation when used
alone [73]. In contrast, Kao et al. reported detrimental effects
when adding it into bovine-derived deproteinized bone [68].
It seems that its use is related with moderate signs of local
inflammation that ultimately can jeopardize graft stability
by disrupting primary wound closure. Therefore, although
rhBMP-2 appears to be a promising alternative to autogenous
bone grafts for alveolar ridge/maxillary sinus augmentation,
dose and carrier optimization are being profoundly studied
to expand its efficacy, use, and clinical application [74].
BMP-7 (Osigraft) (Osteogenic Protein-1 [OP-1]) has been
only studied for sinus augmentation. van der Bergh et al.
pioneered its investigation reporting a small sample case
series of this growth factor embedded into a collagen sponge
compared to autogenous graft. While in two subjects bone-
like tissue was found, the third showed a cyst like gran-
ular tissue mass without purulent content [75]. Hence, no
robust conclusion with regard to safety and efficacy could
be reached. Corinaldesi et al. compared the use of rhBMP-
7 + deproteinized bone (0.5 g) versus deproteinized bone
alone (2 g). Results demonstrated no differences in terms of
bone gain. Interestingly, newly formed bone was statistically
greater for the control group (19.9% versus 6.6%) 4 months
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after grafting [76]. Future studies are needed to figure out
the true effect of this specific combination regimen for bone
regeneration.
6.3. Current Understanding. At this moment, BMP-2 rep-
resents a very promising alternative to the so-called “gold
standard” autogenous bone. However, more studies are still
needed to figure out the best carrier as well as to compare
its effectiveness to the popular allogenic human allograft.
The combination usage of BMP with bovine-derived depro-
teinized should be carefully evaluated. In any case, the
induction of bone formation by the TGF-𝛽 proteins is a
cost-effective clinical strategy according to the most recently
published data [61].
7. Teriparatide
7.1. Rationale. Teriparatide consists of parathyroid hormone’s
(PTH) first 34 amino acids. It has been shown to influence
PDL cell survival and to cause osteoblast-like behavior with
increased osteoprotegerin expression [77–79]. As such, the
FDA approved it for the treatment of osteoporosis. Due to its
therapeutic potential, it has been further used in craniofacial
regeneration. In periodontology and implantology, its effect
has been tested in vivo in animal models showing bone
formation in extraction sockets in addition to its effectiveness
in three-dimensional preservation of the alveolar bone [80–
82].
7.2. Evidence/Indications. It has been shown that, with daily
injection of Teriparatide PTH and vitamin D supplement,
a positive treatment outcome (gain clinical attachment lev-
els) was achieved during the surgical treatment of peri-
odontal intrabony defect [83]. Furthermore, this positive
outcome was positively correlated with baseline levels of
1,25-dihydroxyvitamin D3. Kuchler et al. in a feasibility
study found that after a healing period of 9 weeks with
daily injection of Teriparatide (20𝜇g for 28 days), bone-
to-implant contact was indeed higher in the periosteal and
medullary compartment but not the cortical compartment
for the treated group [84]. Nonetheless, bone-volume-per-
tissue-volume did not deviate statistically (was 17.6% versus
15.4% in the control group).
7.3. Current Understanding. At this moment, injected Teri-
paratide PTH showed some positive short-term effect. How-
ever, it does require more long-term studies with larger
sample size. Additionally, delivery route may draw a more
difficult acceptance by patients.
8. Growth Differential Factor-5 (GDF-5)
8.1. Rationale. GDF-5 is another member of the TFG-𝛽
superfamily. For periodontal regeneration, it has been shown,
both in vitro and in vivo, to stimulate PDL cell proliferation,
osteoblast differentiation (early stages), and extracellular
matrix synthesis by both cell types [85]. For implant site
development,GDF-5 has been demonstrated in vivo to induce
bone in ectopic muscle pouches to improve mineralized
tissue formation [86].
8.2. Evidence/Indications. GDF-5 has been approved by FDA
for periodontal regeneration, alveolar bone regeneration, and
sinus augmentation. For periodontal regeneration, it has
been demonstrated to improve clinical attachment level gain
(although not reaching statistical difference) [87]. GDF-5 has
shown similar behavior compared to autologous graft (28%
versus 32%, resp.) when bone formation was assessed at 4
months [88]. Interestingly, higher amount of bone augmen-
tation was found in the composite group of GDF-5 + 𝛽-TCP.
In addition, it has been shown that higher dosage (800𝜇g)
achieved higher amount of bone formation than lower dosage
(400 𝜇g) after 12 weeks in the sinus cavity [89]. Nonetheless
for sinus augmentation information about its effectiveness
is still limited. For lateral ridge augmentation, block grafts
coated with rhGDF-5 achieved similar increase of mineral-
ized tissue when compared to block grafts impregnated with
rhBMP-2. However, when evaluating graft using particulated
bone, sites coated with rhGDF-5 had a significantly lower
mineralized tissue formation at 8 weeks when compared
to grafts coated with rhBMP-2. Moreover, nonmineralized
tissue for both groups revealed high signs of osteocalcin
antigen reactivity [90]. Based on these findings, rhGDF-5
has been shown to possess the potential to enhance bone
formation; however, the outcome may vary with different
carrier [91].
8.3. Current Understanding. At this moment, GDF-5 is a very
promising growth factor for craniofacial regeneration due to
its osteoinductive potential. However, data is still limited to
prove its efficacy and safety in human. Phase II and III clinical
trials are now being carried out to investigate its true effect
in humans. Furthermore, the ideal carrier for delivering this
promising biologic agent remains to be explored.
9. Other Transcription Factors and Regulators
In addition to the previouslymentioned biologic agents, other
critical transcription factors and regulators of osteogenesis as
well as matricellular proteins may become of high interest
in periodontal tissue engineering. Initial studies are being
conducted on the use of Runx2, Osterix (Osx), LIM domain
mineralization protein (LMP) [92], and periostin [93, 94],
among others, with the purpose of regenerating the tooth-
supporting apparatus. Although at a very early stage of these
development, most of these molecules have shown promis-
ing results, such as higher new bone formation, promoted
human PDL cells osteogenesis, and upregulation of alkaline
phosphatase, bone sialoprotein, and BMP2, in vivo [95, 96].
10. Conclusions
The term biologic agent encompasses a variety of different
growth factors and/or signaling molecules with different
origin, mechanisms of action, as well as different targeted
tissues and/or cells in the periodontium. In depth under-
standing of their mechanism of action and indications of
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usage is of paramount importance. While some agents are
still on their infancy, others have obtained FDA approval
for different clinical procedures. Although these biologics
proved to be beneficial in a variety of aspects of periodon-
tal regeneration and bone augmentation procedures, basic
principles of surgery, proper patient, and/or site selection
remain to be essential for predictable clinical outcomes.More
investigation is required to further understand these biologic
agents, providing more information with regard to long-
term effects, proper carrier, and ideal concentration/dosage,
among other confounding factors.
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